Seattle Biotech Looks to Raise Up to $288M Amid Plans to Spin Out Immune Medicine Business

Seattle-based Adaptive Biotechnologies announced plans to raise up to $287.5M in convertible senior notes as it prepares to spin out its immune medicine businesses by the end of the year while retaining its minimal residual disease business.